‘Black Panther’ Nanotechnology versus Cancer

In the Marvel Universe, if you compare the suits of Iron Man and Black Panther, you quickly realize that one is bulky and consumes a lot of energy just moving or flying around. The other is so thin, and efficient capable of absorbing and emitting mass amounts of kinetic energy. The latter is similar to ‘thin’ high atomic number nanoparticles that can absorb and emit  micrometer-range missile-like electrons with kinetic energy to damage cancer cells.  In this highly interactive presentation, you will learn how such nanoparticles can be leveraged  in cancer treatment to eliminate cancer cells with great efficacy, including eliminating cancer that has spread to other parts of the body.

Dr Ngwa is the Director of Global Health Catalyst (GHC) at Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School. The GHC is dedicated to catalyzing high impact international collaborations to eliminate global health disparities with a major focus on cancer. The work has led to many productive collaborations in global oncology research, education and care, and is helping shape the emerging field of global radiation oncology. Besides serving as faculty Director of the GHC, Dr Ngwa’s work integrates research, clinical service, and teaching, with current focus on clinical translation of technologies/approaches that can increase access to quality cancer treatment including smart radiotherapy biomaterials (Tiny drones to Target cancer). The award-winning drone technology is designed to eliminate both local and metastatic tumors with minimal collateral damage or side effects. The drones can be employed to deliver different drug payloads (including immunotherapy drugs and cannabinoids) precisely to disease sites or targets, with greater therapeutic efficacy. In radiation Oncology, Dr Ngwa is leading international research efforts to introduce a new radiotherapy approach without the need of currently used margins, such as the clinical target volume.